Contract manufacturing of vaccines for companies in different regions of the world, using recombinant or traditional technology through cell culture, fermentation, and molecular purification.

Development of lyophilized products for third parties, under a fully automated process and in modern packaging facilities for injectables, inaugurated in 2006.

Quality control by means of molecular biology techniques such as PCR, ELISA and mAbs, among others. Control of vaccine and field strains.

Vaccine response studies in laboratory animals and target species.